Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenues, net $ 8,365 $ 24,200 $ 40,885 $ 100,824
Cost of revenues 6,038 12,227 21,590 41,453
Gross profit 2,327 11,973 19,295 59,371
Operating expenses:        
Diagnostic expenses 132 2,398 1,932 8,869
General and administration 8,245 7,512 26,480 21,643
Research and development 428 110 1,144 174
Total operating expenses 8,805 10,020 29,556 30,686
(Loss) income from operations (6,478) 1,953 (10,261) 28,685
Interest income, net 1 25 39 123
Interest expense (275) (201) (781) (635)
Change in fair value of investment securities 0 0 0 (76)
Other income (loss) (33) 0 (132) 0
(Loss) income from operations before income taxes (6,785) 1,777 (11,135) 28,097
Income tax benefit (expense) 1,644 (809) 3,104 (7,190)
(Loss) income from operations after income taxes (5,141) 968 (8,031) 20,907
Net (loss) income (5,141) 968 (8,031) 20,907
Other comprehensive (loss) income:        
Unrealized gain (loss) on marketable debt securities (2,032) (51) (2,201) (112)
Total comprehensive (loss) income $ (7,173) $ 917 $ (10,232) $ 20,795
Earnings per share:        
Earnings (loss) per share, basic (in dollars per share) $ (0.30) $ 0.06 $ (0.47) $ 1.33
Earnings (loss) per share, diluted (in dollars per share) $ (0.30) $ 0.06 $ (0.47) $ 1.10
Weighted average common shares outstanding:        
Weighted average common shares outstanding, basic (in shares) 17,175 15,898 16,924 15,712
Weighted average common shares outstanding, diluted (in shares) 17,175 20,248 16,924 19,504